Drug class: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor; monoclonal antibody (1) Mechanism of Action Evolocumab is a monoclonal antibody that binds to circulating PCSK9 and prevents it from binding to low-density lipoprotein receptors (LDL-R) on hepatocytes. In general, PCSK9 promotes LDL-R degradation after low-density lipoprotein (LDL) is internalized, reducing the number of receptors available to remove LDL from the circulation. By inhibiting PCSK9, ev